Commercial and Pipeline Insight: Infertility

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-10-10

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.


Scope

  • Analysis of patient potential, unmet needs, market dynamics, and clinical trial design in infertility, supported by opinion leader comment
  • Assessment of pipeline drugs and future treatment trends and their impact on prescribing patterns and behavior
  • Patient based and sales based market forecasts to 2016, the latter providing a breakdown by region, drug class, marketed brands and pipeline drugs
  • Coverage of emerging infertility markets which, in light of reproductive tourism, may offer revenue growth potential


    • Report Highlights
    Key differentiators will permit Organon's Org-36286 (corifollitropin alpha) and Merck Serono's Pergoveris (r-FSH and r-LH), to cannibalize some share from their proprietors' franchise leading therapies. However, these agents do not appear to satisfy unmet need and this will prevent sales from rivaling Puregon and Menopur (hMG).

    The lack of education of non-specialist physicians limits the number of women receiving treatment. It should be a primary goal of the market to make these doctors more knowledgeable and to implement incentives to encourage patient referral.

    New opportunities exist in the development of products to support embryological techniques; cryopreservation, microarrays and in vitro maturation. These procedures will expand the treatable patient population as all women with the intention of preserving and protecting embryos will be eligible for treatment, not just those that are infertile.


    Reasons to Purchase

  • Quantify the future size of the infertility market and the number of women eligible for infertility treatment to 2016 in the US, 5EU, and Japan
  • Understand unmet needs and opportunities in the infertility market based on key opinion leader comments
  • Benchmark key late-stage infertility compounds against current market leading brands

    • Table of Contents

    Other users found this report page using the following search terms: infertility fertilization market infertility fertility pergoveris menopur pipeline puregon serono merck ferring

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.